Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 915268 | ISIN: FR0000063737 | Ticker-Symbol: BAQ
Frankfurt
22.01.25
08:02 Uhr
45,500 Euro
+0,400
+0,89 %
Branche
Telekom
Aktienmarkt
Sonstige
1-Jahres-Chart
AUBAY SA Chart 1 Jahr
5-Tage-Chart
AUBAY SA 5-Tage-Chart
RealtimeGeldBriefZeit
45,60046,65020:44
Actusnews Wire
164 Leser
Artikel bewerten:
(1)

AUBAY: 2024 revenue meets target at EUR 540.3 million - Organic growth of 3.3% in second-half 2024

Finanznachrichten News
In € millionQ4 2024*Q4 2023Change2024*2023Change
France72.071.9+0.2%283.3280.5+1.0%
International66.863.6+5.1%257.0253.6+1.3%
Total138.8135.5+2.5%540.3534.1+1.2%

*Currently being audited

Aubay posted revenue of €540.3 million for 2024, up 1.2% in organic terms, including a 3.3% increase in the second half of the year. This revenue lies within the target range announced at the start of the year. In line with expectations, this performance stemmed from a 93.7% productivity rate for consultants, up 0.9 point, and continued sales price increases, which offset the slight decline in headcount, which was slightly more marked in international markets than in France.

Annual revenue in France amounted to €283.3 million, up 1.0% in line with our expectations. In an overall market context in which many customers are still exercising caution, Aubay's key sectors - banking, finance and insurance - are proving resilient. Productivity remained virtually stable in France, while the positive price effect offset the slight decline in the workforce.

Internationally, the fourth quarter saw remarkable organic growth of 5.1%. Aubay benefited from a favorable calendar effect and a significant improvement in performance in Italy. Overall, like our French customer portfolio, our international portfolio is well-balanced, with limited exposure to the economic sectors most sensitive to cyclical conditions. Increased productivity and the price effect contributed positively to this quarterly growth.

Restructuring efforts in Italy are beginning to reap benefits. After several quarters of revenue remaining stable at around €25/26 million, growth in the fourth quarter came out at 8%, driven by a very positive calendar effect, an improved productivity rate and an upturn in productive headcount since the end of 2024.

Spain and Portugal also saw growth over the year thanks to the positive trend in productivity rate and prices, which offset the decline in the number of productive employees at the start of the year, which has now stabilized.

Operating margin from ordinary activities at the middle of the target range

Operating margin is expected to be in line with last year's performance, and in the middle of the 8.5% to 9.5% target range set at the start of 2024.

Recruiting cautiously in a more demanding market

In all regions, higher customer expectations and the desire to preserve margins have led Aubay to manage recruitment cautiously.

In the fourth quarter, net recruitment was up by 43 employees, reversing the trend seen in the first three quarters. The Group is therefore starting 2025 with a workforce of 7,483 employees (vs. 7,779 at December 31, 2023).

Outlook for 2025: stable performance pending market recovery

Aubay's business environment at the start of the year remains unchanged from 2024. The number of projects remains relatively high, as technological changes and regulatory impacts continue to dictate underlying trends. However, the lack of macroeconomic visibility may lead some players to remain conservative in their IT investment strategies.

In this context, still buoyed by the improvement in the productivity rate and the price effect, Aubay expects to continue its growth trajectory in 2025, aiming for:

  • organic growth of between 0% and 3%, i.e., annual revenue within the range of €540 million and €556 million;
  • recurring operating margin between 8.5% and 9.5%.

Next publication: The full-year 2024 results will be published on March 19, 2025 after the close of trading.

2025 financial calendar

2025/2026 financial calendarDate
Q1 2025 revenueWednesday April 23, 2025
Q2 2025 revenueWednesday July 23, 2025
H1 2025 resultsWednesday September 17, 2025
Financial analysts meetingThursday September 18, 2025
Q3 2025 revenueWednesday October 22, 2025
Q4 2025 revenueWednesday January 28, 2026
2025 annual resultsWednesday March 18, 2026

Glossary

Organic revenue growth: this refers to growth calculated for a constant scope of activity for a given period, excluding revenue from companies that were acquired or sold during the period. As Aubay conducts most of its business in the euro zone, any impact from changes in exchange rates is minimal.

Operating profit from ordinary activities: this indicator corresponds to operating income before the cost of free shares and other income and expenses that are unusual, significant or infrequent and that are booked separately in order to facilitate understanding of an entity's recurring operating performance.

Operating margin from ordinary activities: this indicator, which is expressed as a percentage, is the ratio of operating income from ordinary activities to revenue.

Net debt or net cash: this indicator represents the difference between an entity's cash and debt. If the result is negative, it is referred to as net debt. If it is positive, it is referred to as net cash.

About Aubay

Aubay is a digital services company working alongside some of the biggest names in the Banking, Finance, Insurance, Manufacturing, Energy, Transport and Telecoms sectors. Aubay has 7,483 employees in seven countries (France, Belgium, Luxembourg, Italy, Spain, Portugal and the United Kingdom). Aubay generated revenue of €540.3 million in 2024.

Euronext, Compartment: B - ISIN FR0000063737-AUB - Reuters AUBT.PA - Bloomberg AUB:FP

Contacts

Amaury Dugast - Actus Finance - Tel: +33 (0)1 53 67 36 74 - E-mail: adugast@actus.fr

David Fuks - Co-Chief Operating Officer - Finance Department - Tel.: +33 (0)1 46 10 67 67 - E-mail: dfuks@aubay.com

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: lplrksdqlGaclm+bZMeabWKYZm1qxpSVlmHImmabYpfGanKWyJyXmsWXZnFqm2ht
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-89637-communique-financier-aubay-t4-2024-veng.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2025 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.